Flock, smart-money disclosures made readable

Travere Therapeutics Inc

TVTXNASDAQ · US

Sign in for alerts Sign in to add to portfolio

Holders

Ownership

Ownership data not yet available for this security.

Disclosure timeline

REDUCEDT+30
Calvin Sandra
Travere Therapeutics Inc · NASDAQ
−300 sh · $19.1K
Filed 17 Sept 2026SEC Form 4view source
ACQUIREDT+30
Dube Eric M
Travere Therapeutics Inc · NASDAQ
+108,493 sh · $2.5M
Filed 17 Sept 2026SEC Form 4view source
REDUCEDT+30
Rote William E.
Travere Therapeutics Inc · NASDAQ
−3,000 sh · $191.0K
Filed 17 Sept 2026SEC Form 4view source
REDUCEDT+30
Dube Eric M
Travere Therapeutics Inc · NASDAQ
−96,125 sh · $6.1M
Filed 17 Sept 2026SEC Form 4view source
ACQUIREDT+30
Dube Eric M
Travere Therapeutics Inc · NASDAQ
+95,666 sh · $2.2M
Filed 17 Sept 2026SEC Form 4view source
REDUCEDT+30
Rote William E.
Travere Therapeutics Inc · NASDAQ
−29,021 sh · $1.8M
Filed 17 Sept 2026SEC Form 4view source
ACQUIREDT+30
Rote William E.
Travere Therapeutics Inc · NASDAQ
+57,500 sh · $1.5M
Filed 17 Sept 2026SEC Form 4view source
ACQUIREDT+30
Rote William E.
Travere Therapeutics Inc · NASDAQ
+55,000 sh · $850.3K
Filed 17 Sept 2026SEC Form 4view source
REDUCEDT+30
Cline Christopher R.
Travere Therapeutics Inc · NASDAQ
−1,900 sh · $121.0K
Filed 17 Sept 2026SEC Form 4view source
ACQUIREDT+30
Inrig Jula
Travere Therapeutics Inc · NASDAQ
+32,395 sh · $289.3K
Filed 17 Sept 2026SEC Form 4view source

Announcements

No announcements on record for this security.

Show the latest 50

REDUCEDT+30
Dube Eric M
Travere Therapeutics Inc · NASDAQ
−270 sh · $17.6K
Filed 17 Sept 2026SEC Form 4view source
REDUCEDT+30
Reed Elizabeth E
Travere Therapeutics Inc · NASDAQ
−1,400 sh · $89.2K
Filed 17 Sept 2026SEC Form 4view source
ACQUIREDT+30
Heerma Peter
Travere Therapeutics Inc · NASDAQ
+100,000 sh · $1.1M
Filed 17 Sept 2026SEC Form 4view source
REDUCEDT+30
Reed Elizabeth E
Travere Therapeutics Inc · NASDAQ
−13,874 sh · $869.0K
Filed 17 Sept 2026SEC Form 4view source
REDUCEDT+30
Rote William E.
Travere Therapeutics Inc · NASDAQ
−270 sh · $17.6K
Filed 17 Sept 2026SEC Form 4view source
ACQUIREDT+30
Heerma Peter
Travere Therapeutics Inc · NASDAQ
+39,283 sh · $1.1M
Filed 17 Sept 2026SEC Form 4view source
ACQUIREDT+30
Heerma Peter
Travere Therapeutics Inc · NASDAQ
+1,381 sh · $30.9K
Filed 17 Sept 2026SEC Form 4view source
REDUCEDT+30
Dube Eric M
Travere Therapeutics Inc · NASDAQ
−101,691 sh · $6.6M
Filed 17 Sept 2026SEC Form 4view source
REDUCEDT+30
Cline Christopher R.
Travere Therapeutics Inc · NASDAQ
−27,473 sh · $1.7M
Filed 17 Sept 2026SEC Form 4view source
ACQUIREDT+30
Calvin Sandra
Travere Therapeutics Inc · NASDAQ
+1,250 sh · $28.0K
Filed 17 Sept 2026SEC Form 4view source
ACQUIREDT+30
Heerma Peter
Travere Therapeutics Inc · NASDAQ
+55,000 sh · $850.3K
Filed 17 Sept 2026SEC Form 4view source
REDUCEDT+30
Heerma Peter
Travere Therapeutics Inc · NASDAQ
−79,113 sh · $5.0M
Filed 17 Sept 2026SEC Form 4view source
REDUCEDT+30
Reed Elizabeth E
Travere Therapeutics Inc · NASDAQ
−21,926 sh · $1.4M
Filed 17 Sept 2026SEC Form 4view source
REDUCEDT+30
Dube Eric M
Travere Therapeutics Inc · NASDAQ
−3,102 sh · $197.4K
Filed 17 Sept 2026SEC Form 4view source
ACQUIREDT+30
Heerma Peter
Travere Therapeutics Inc · NASDAQ
+17,717 sh · $476.2K
Filed 17 Sept 2026SEC Form 4view source
ACQUIREDT+30
Calvin Sandra
Travere Therapeutics Inc · NASDAQ
+2,500 sh · $68.8K
Filed 17 Sept 2026SEC Form 4view source
REDUCEDT+30
Rote William E.
Travere Therapeutics Inc · NASDAQ
−65,104 sh · $4.1M
Filed 17 Sept 2026SEC Form 4view source
REDUCEDT+30
Dube Eric M
Travere Therapeutics Inc · NASDAQ
−99,716 sh · $6.3M
Filed 17 Sept 2026SEC Form 4view source
REDUCEDT+30
Heerma Peter
Travere Therapeutics Inc · NASDAQ
−71,938 sh · $4.5M
Filed 17 Sept 2026SEC Form 4view source
REDUCEDT+30
Heerma Peter
Travere Therapeutics Inc · NASDAQ
−8,282 sh · $538.9K
Filed 17 Sept 2026SEC Form 4view source
REDUCEDT+30
Heerma Peter
Travere Therapeutics Inc · NASDAQ
−1,431 sh · $93.5K
Filed 17 Sept 2026SEC Form 4view source
REDUCEDT+30
Heerma Peter
Travere Therapeutics Inc · NASDAQ
−1,400 sh · $89.1K
Filed 17 Sept 2026SEC Form 4view source
REDUCEDT+30
Heerma Peter
Travere Therapeutics Inc · NASDAQ
−93,604 sh · $5.9M
Filed 17 Sept 2026SEC Form 4view source
REDUCEDT+30
Rote William E.
Travere Therapeutics Inc · NASDAQ
−47,746 sh · $3.0M
Filed 17 Sept 2026SEC Form 4view source
REDUCEDT+30
Calvin Sandra
Travere Therapeutics Inc · NASDAQ
−4,275 sh · $265.6K
Filed 17 Sept 2026SEC Form 4view source
ACQUIREDT+30
Heerma Peter
Travere Therapeutics Inc · NASDAQ
+36,526 sh · $326.2K
Filed 17 Sept 2026SEC Form 4view source
REDUCEDT+30
Reed Elizabeth E
Travere Therapeutics Inc · NASDAQ
−300 sh · $19.6K
Filed 17 Sept 2026SEC Form 4view source
ACQUIREDT+30
Rote William E.
Travere Therapeutics Inc · NASDAQ
+39,000 sh · $984.8K
Filed 17 Sept 2026SEC Form 4view source
REDUCEDT+30
Heerma Peter
Travere Therapeutics Inc · NASDAQ
−27,421 sh · $1.7M
Filed 17 Sept 2026SEC Form 4view source
REDUCEDT+30
Inrig Jula
Travere Therapeutics Inc · NASDAQ
−17,284 sh · $1.1M
Filed 17 Sept 2026SEC Form 4view source
REDUCEDT+30
Dube Eric M
Travere Therapeutics Inc · NASDAQ
−6,802 sh · $441.8K
Filed 17 Sept 2026SEC Form 4view source
ACQUIREDT+30
Dube Eric M
Travere Therapeutics Inc · NASDAQ
+195,841 sh · $4.6M
Filed 17 Sept 2026SEC Form 4view source
REDUCEDT+30
Cline Christopher R.
Travere Therapeutics Inc · NASDAQ
−20,735 sh · $1.3M
Filed 17 Sept 2026SEC Form 4view source
REDUCEDT+30
Cline Christopher R.
Travere Therapeutics Inc · NASDAQ
−400 sh · $26.1K
Filed 17 Sept 2026SEC Form 4view source
REDUCEDT+30
Inrig Jula
Travere Therapeutics Inc · NASDAQ
−400 sh · $26.1K
Filed 17 Sept 2026SEC Form 4view source
ACQUIREDT+30
Calvin Sandra
Travere Therapeutics Inc · NASDAQ
+1,625 sh · $33.2K
Filed 17 Sept 2026SEC Form 4view source
REDUCEDT+30
Dube Eric M
Travere Therapeutics Inc · NASDAQ
−28,796 sh · $1.8M
Filed 17 Sept 2026SEC Form 4view source
REDUCEDT+30
Inrig Jula
Travere Therapeutics Inc · NASDAQ
−25,390 sh · $1.6M
Filed 17 Sept 2026SEC Form 4view source
ACQUIREDT+30
Heerma Peter
Travere Therapeutics Inc · NASDAQ
+8,282 sh · $185.5K
Filed 17 Sept 2026SEC Form 4view source
ACQUIREDT+30
Rote William E.
Travere Therapeutics Inc · NASDAQ
+350 sh · $6.3K
Filed 17 Sept 2026SEC Form 4view source